David Younger is a bioengineer and started his biotech journey directly after his PhD. David’s scientific research was focused on the application of synthetic biology techniques for high-throughput screening of protein-protein interactions. In 2017 David co-founded A-Alpha Bio as a spin-out from the University of Washington. A-Alpha Bio applies synthetic biology to reprogram yeast mating and generate high quality protein interaction data at scale. Its AlphaSeq technology enables high-throughput, quantitative characterization of protein–protein binding interactions without requiring purified recombinant proteins to identify molecular glues.